EGFR and hepatocellular carcinoma: The overexpression of HIF-2α, similar to that of HIF-1α, has also been shown to be associated with poor prognosis in patients with HCC [180], and the sorafenib-induced upregulation of HIF-2α is associated with drug resistance through the activation of the TGFα/epidermal growth factor receptor (EGFR) pathway [181].